“
TL;DR
In a guinea pig form-deprivation myopia model, retinal VIP mRNA and protein expressions were significantly up-regulated, and 1% atropine treatment attenuated the myopic shift while reducing VIP expression back toward normal levels.
BMC Ophthalmology · 9 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
In a guinea pig form-deprivation myopia model, retinal VIP mRNA and protein expressions were significantly up-regulated, and 1% atropine treatment attenuated the myopic shift while reducing VIP expression back toward normal levels.
Thirty-three-week-old guinea pigs were assigned to normal control, form-deprivation myopia (FDM), and FDM treated with 1% atropine groups (n=10 each). Diopter and axial length were measured at 0, 2, and 4 weeks; eyeballs were harvested at week four for H&E staining, immunohistochemistry, and in situ hybridization. The FDM group showed a myopic shift with retinal, choroidal, and scleral structural changes. VIP mRNA and protein expressions were significantly up-regulated in the FDM retina. Atropine treatment attenuated the myopic shift, reduced axial length elongation, improved fundus morphological changes, and considerably reduced retinal VIP expression. The authors suggest that upregulated VIP may participate in myopia pathogenesis and that atropine may control myopia partly by modulating VIP signaling.